We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

29 hedge funds and large institutions have $4.9M invested in Gyre Therapeutics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less funds holding

Funds holding: 31 → 29 (-2)

22% less capital invested

Capital invested by funds: $6.31M → $4.9M (-$1.41M)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

78% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 9

Holders
29
Holders Change
-2
Holders Change %
-6.45%
% of All Funds
0.77%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
2
Increased
2
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$114K
2
Citadel Advisors
Citadel Advisors
Florida
+$24.6K
3
WS
Wedbush Securities
California
+$10.1K
4
Bank of America
Bank of America
North Carolina
+$2.11K

Top Sellers

1
BI
BVF Inc
California
-$141K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$47.4K
3
DCM
DG Capital Management
New York
-$36.5K
4
Morgan Stanley
Morgan Stanley
New York
-$18.1K
5
Goldman Sachs
Goldman Sachs
New York
-$10.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
EWM
1
Essex Woodlands Management
Texas
$1.45M – – –
BI
2
BVF Inc
California
$1.05M -$141K -935 -11%
NMC
3
NEA Management Company
Maryland
$789K – – –
UBS Group
4
UBS Group
Switzerland
$428K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$249K -$47.4K -314 -15%
Renaissance Technologies
6
Renaissance Technologies
New York
$227K +$114K +754 +83%
BIT
7
BlackRock Institutional Trust
California
$186K -$10.6K -70 -5%
CCM
8
Colorado Capital Management
Colorado
$95K – – –
DCM
9
DAFNA Capital Management
California
$86K – – –
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$72K -$3.62K -24 -4%
Goldman Sachs
11
Goldman Sachs
New York
$51K -$10.7K -71 -16%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$31K – – –
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$30K – – –
NMIMC
14
Northwestern Mutual Investment Management Company
Wisconsin
$28K – – –
WS
15
Wedbush Securities
California
$25K +$10.1K +67 +56%
DCM
16
DG Capital Management
New York
$22K -$36.5K -242 -60%
Citadel Advisors
17
Citadel Advisors
Florida
$22K +$24.6K +163 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$21K -$5.13K -34 -18%
AIA
19
Arbor Investment Advisors
North Carolina
$18K – – –
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$16K – – –
BJ
21
BlackRock Japan
Japan
$2K -$151 -1 -5%
NFA
22
Nationwide Fund Advisors
Ohio
$2K – – –
Bank of America
23
Bank of America
North Carolina
$2K +$2.11K +14 New
BFA
24
BlackRock Fund Advisors
California
$1K – – –
PAM
25
Panagora Asset Management
Massachusetts
$1K – – –
1
2

GYRE Hedge Fund Activity: Q3 2016 in Review

29 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2016, worth a combined $4.9M — down 22% from $6.31M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of GYRE and 2 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $114K. The largest seller was BVF Inc, cutting an estimated $141K.

  • 29 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2016, down from 31 in Q2 2016.
  • Funds reported $4.9M of Gyre Therapeutics stock for Q3 2016, down 22% quarter-over-quarter.
  • 2 funds opened new Gyre Therapeutics positions in Q3 2016 and 4 closed out, a net change of -2 holders.
  • The largest Gyre Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $114K added.
  • The largest Gyre Therapeutics seller in Q3 2016 was BVF Inc, an estimated $141K sold.

Based on aggregated 13F filings for Q3 2016.